Inebilizumab (Uplizna)

Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec. This review assesses inebilizumab (Uplizna), 10 mg/mL, single-dose vials containing 100 mg inebilizumab in 10 mL solution, IV infusion. Indication: Inebilizumab for injection is indicated for the treatment of IgG4-RD in adult patients to reduce the frequency of flares.